Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 23Leukemia, Myelogenous, Chronic, BCR-ABL Positive 9Leukemia 9Leukemia, Myeloid, Chronic-Phase 7Recurrence 4Hematologic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myelodysplastic Syndromes 2Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia, Promyelocytic, Acute 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia, Myeloid 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Biphenotypic, Acute 1Hematologic Tumors 1Congenital Abnormalities 1Blast Crisis 1

Interventions

Cytarabine 84Etoposide 31Daunorubicin 31Mitoxantrone 26Idarubicin 26Filgrastim 24Busulfan 20Peripheral Blood Stem Cell Transplantation 19Cyclophosphamide 17fludarabine phosphate 15Gemtuzumab 14tipifarnib 11Azacitidine 11Methotrexate 10Clofarabine 10sargramostim 9Gene Expression Profiling 9Flow Cytometry 9Cyclosporine 9Tacrolimus 8Radiotherapy 8Granulocyte Colony-Stimulating Factor 7Decitabine 7Antilymphocyte Serum 7alvocidib 6Topotecan 6Bortezomib 6Arsenic Trioxide 6valspodar 5aldesleukin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Monocytic, Acute × Homoharringtonine × Clear all
NCT02029417 2016-05-09

Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Roswell Park Cancer Institute

Phase 2 Terminated
2 enrolled 6 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡